Interleukin-17 Induces VEGFA Expression In LNCAP Cells
Vascular endothelial growth factor A (VEGFA) is a key contributor to the formation of new blood vessels and angiogenesis is commonly seen in wound healing, cancer, and inflammatory diseases. However, whether interleukin-17 (IL-17) can induce the expression of VEGFA in prostate cancer cells remains unknown. In this study, Western blot analysis and reverse transcription-polymerase chain reaction (RT-PCR) analysis validated that expression of VEGFA in human prostate cancer LNCaP cells under IL-17 treatment was significantly higher than the untreated control group. The conditioned culture medium (CM) of LNCaP cells treated with IL-17 increased tube number, tube nodes, and tube length formed by human umbilical vein endothelial cells (HUVEC) in tube formation assays, compared with the control CM without IL-17 treatment. Collectively, these findings reveal that the expression of VEGFA is induced by IL-17 in LNCaP prostate cancer cells, which leads to increased angiogenesis of HUVEC cells. This study suggests that expression of VEGFA may be up-regulated by IL-17 in prostate cancer to enhance tumor angiogenesis.